Selective targeting of glucagon‐like peptide‐1 signalling as a novel therapeutic approach for cardiovascular disease in diabetes

• Published in: British journal of pharmacology 2015-02, Vol.172 (3), p.721-736
• Main Authors: Tate, Mitchel, Chong, Aaron, Robinson, Emma, Green, Brian D, Grieve, David J
• Format: Article
• Language: English
• Subjects: Cardiovascular disease; Cardiovascular Diseases - complications; Cardiovascular Diseases - drug therapy; Cardiovascular Diseases - metabolism; Diabetes; Diabetes Mellitus, Type 2 - complications; Diabetes Mellitus, Type 2 - drug therapy; Diabetes Mellitus, Type 2 - metabolism; Glucagon-Like Peptide 1 - antagonists & inhibitors; Glucagon-Like Peptide 1 - metabolism; Humans; Hypoglycemic Agents - pharmacology; Hypoglycemic Agents - therapeutic use; Medical research; Reviews; Risk Factors; Signal Transduction - drug effects
• ISSN: 0007-1188; 1476-5381
• DOI: 10.1111/bph.12943

Glucagon‐like peptide‐1 (GLP‐1) is an incretin hormone whose glucose‐dependent insulinotropic actions have been harnessed as a novel therapy for glycaemic control in type 2 diabetes. Although it has been known for some time that the GLP‐1 receptor is expressed in the CVS where it mediates important physiological actions, it is only recently that specific cardiovascular effects of GLP‐1 in the setting of diabetes have been described. GLP‐1 confers indirect benefits in cardiovascular disease (CVD) under both normal and hyperglycaemic conditions via reducing established risk factors, such as hypertension, dyslipidaemia and obesity, which are markedly increased in diabetes. Emerging evidence indicates that GLP‐1 also exerts direct effects on specific aspects of diabetic CVD, such as endothelial dysfunction, inflammation, angiogenesis and adverse cardiac remodelling. However, the majority of studies have employed experimental models of diabetic CVD and information on the effects of GLP‐1 in the clinical setting is limited, although several large‐scale trials are ongoing. It is clearly important to gain a detailed knowledge of the cardiovascular actions of GLP‐1 in diabetes given the large number of patients currently receiving GLP‐1‐based therapies. This review will therefore discuss current understanding of the effects of GLP‐1 on both cardiovascular risk factors in diabetes and direct actions on the heart and vasculature in this setting and the evidence implicating specific targeting of GLP‐1 as a novel therapy for CVD in diabetes.